BNT326

Other Medications

Description

BNT326 is an experimental treatment being studied in clinical trials for various advanced cancers, including colorectal cancer. It is currently in Phase 1 trials, which means researchers are primarily looking at its safety and determining the best way to give it. The trial involving colorectal cancer (NCT07070232) is exploring BNT326, sometimes in combination with another investigational drug called pumitamig, in patients whose cancer has progressed after at least two prior treatments (second-line or higher). The trial is recruiting participants. The specific way BNT326 works is still under investigation.

Mechanism of Action

BNT326 is an investigational treatment. The specific molecular target or mechanism of action is being studied in clinical trials. It is being evaluated both as a single treatment and in combination with other therapies.

Side Effects

As BNT326 is an investigational drug in early-phase trials (Phase 1) The full range of potential side effects is still being evaluated. Information about side effects from these trials is not yet widely available. Researchers are carefully monitoring participants in the trials to assess safety.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT07070232 Phase 1

Recruiting

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

United States, Australia, Belgium, Germany, Italy, Spain, Turkey (Türkiye), Unit

Quick Info

Category	Other Medications
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.